Clinical Trial Update: A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus [Phase 2]

View source ↗

Summary

Genentech's Phase 2 trial of GDC-0853 for moderate to severe systemic lupus erythematosus has completed, with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• GDC-0853

Snippet

Sponsor: Genentech, Inc. | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: COMPLETED | Results posted: 2020-07-07